1. Home
  2. Vol 54, No 2 (2022)
  3. Yulianti

COVID-19 Associated Pulmonary Aspergillosis: A Case Series

Mira Yulianti, Christian Johan, Eric Daniel Tenda, Gurmeet Singh, Herikurniawan Herikurniawan, I Putu Eka Krisnha Wijaya

Abstract


Coronavirus disease 2019 (COVID-19) has been a worldwide pandemic with several problems, one of which is the lack of definitive treatment. COVID-19-associated pulmonary aspergillosis (CAPA), the presence of invasive pulmonary aspergillosis (IPA) in COVID-19 patients, is one of the concerning secondary infections associated with higher mortality and worse clinical outcomes. Diagnosing CAPA may be challenging due to the possible absence of classic host factors and clinical symptoms or obscured radiological findings. We described two CAPA cases, which were suspected due to persistent respiratory failure despite standard treatment of COVID-19 with additional therapies and antimicrobial agents for secondary infections, eventually diagnosed with serum galactomannan testing. Clinical conditions of both patients improved significantly after the administration of voriconazole. This case series emphasizes the importance of being aware of clinical suspicions indicating CAPA followed by galactomannan testing as a relatively fast, noninvasive test for its diagnosis, which leads to appropriate antifungal treatment.


Keywords


Aspergillosis; Aspergillus; COVID-19; COVID-19-associated pulmonary aspergillosis (CAPA), invasive pulmonary aspergillosis (IPA)

References


Chong WH, Neu KP. Incidence, diagnosis and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA): a systematic review. J Hosp Infect. 2021;113:115–29.

Mitaka H, Kuno T, Takagi H, Patrawalla P. Incidence and mortality of COVID-19-associated pulmonary aspergillosis: A systematic review and meta-analysis. Mycoses. 2021;1–9. doi: 10.1111/myc.13292.

Koehler P, Bassetti M, Chakrabarti A, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021;21:e149–62. doi: 10.1016/S1473-3099(20)30847-1.

Arastehfar A, Carvalho A, van de Veerdonk FL, et al. COVID-19 associated pulmonary aspergillosis (CAPA)—from immunology to treatment. J Fungi. 2020;6:1–17. doi: 10.3390/jof6020091

Ye Z, Zhang Y, Wang Y, Huang Z, Song B. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review. Eur Radiol. 2020;30:4381–9. doi: 10.1007/s00330-020-06801-0

Denning D. Aspergillosis. In: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editors. Harrison’s principles of internal medicine. 20th ed. New York: McGraw-Hill; 2018. p. 1352–6.

Peter Donnelly J, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis. 2020;71:1367–76. doi: 10.1093/cid/ciz1008

Koehler P, Cornely OA, Böttiger BW, et al. COVID-19 associated pulmonary aspergillosis. Mycoses. 2020;63:528–34. doi: 10.1111/myc.13096

Blot SI, Taccone FS, Van Den Abeele AM, et al. A Clinical algorithm to diagnose invasive pulmonary Aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2012;186:56–64. doi: 10.1164/rccm.201111-1978OC.

Karapinar D. A review of a diagnostic tool: Galactomannan. J Immunol Sci. 2018;2:38–42. doi: 10.29245/2578-3009/2018/5.1137

Maertens J, Theunissen K, Verbeken E, et al. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol. 2004;126:852–60. doi: 10.1111/j.1365-2141.2004.05140.x

Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: Variables that affect performance. J Infect Dis. 2004;190:641–9. doi: 10.1086/422009.


Full Text: PDF

Refbacks

  • There are currently no refbacks.